F36C also induced cellular immunity.

(A) Schematic diagrams of the structures of F37A, F36C and MT825. F36C has a core structure similar to that of F37A, but lacks the class II OVA epitope. (B) F36C also induced a significant CTL response, as compared to MT825. Mice were intraperitoneally immunized with antigens plus MPL (n = 3 per condition). CTL responses were assessed as described in Figure 4. (C) A representative flow cytometry analysis performed in tetramer assay (left panels). An increase in the OVA-specific CD8 T-cells was observed following immunization with F37A and F36C (right panel). (D) Immunization with F36C plus MPL inhibited tumor growth to the same degree as immunization with F37A plus MPL. Bars represent mean ± SD for a group of 5 mice. Each dot indicates the tumor volume in an individual mouse 3-week after tumor inoculation. (E) The MHC class II epitope in F37A may function during the effector phase of tumor immunotherapy. Survival plots of mice immunized with F37A/MPL, F36C/MPL, or MT825/MPL. Mice immunized with either F37A/MPL or F36C/MPL survived longer than the unimmunized control group. Moreover, mice immunized with F37A survived longer than those immunized with F36C (n = 8 mice per group).